Literature DB >> 291476

Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro.

D V Jackson, R A Bender.   

Abstract

L1210 murine leukemia and CEM human lymphoblastoid leukemia cells were exposed to vincristine sulfate in vitro. The response of these cell lines to this agent was measured by the colony-forming ability of L1210 cells in soft agar and inhibition of growth of CEM in suspension culture. Incremental increases of vincristine concentrations in excess of 2 x 10(-9) M produced a progressive reduction of survival of L1210 cells and suppression of CEM growth under the condition of constant drug exposure. A maximum cytotoxic effect was reached with drug concentrations between 10(-8) and 10(-7) M. When L1210 cells were exposed to vincristine for a variable length of time ranging from 0.5 to 24 hr, 10(-7) M produced a noticeable cytotoxic effect following an incubation of only 30 min. A 50% cell kill of L1210 cells and a 50% reduction of CEM cell growth were produced by 10(-7) M following a 1- to 3-hr period of exposure; 6 to 12 hr were required to produce a similar effect at a vincristine concentration of 10(-8) M. Therefore, the antitumor effect of vincristine is critically dependent on both concentration and duration of exposure. These data suggest the possibility that the effectiveness of vincristine as an antitumor agent could be enhanced if methods are developed to prolong exposure of neoplastic tissues for longer periods of time than currently produced by conventional methods of administration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 291476

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Authors:  Marsilius Mues; Laila Karra; Damia Romero-Moya; Anica Wandler; Matthew J Hangauer; Olga Ksionda; Yvonne Thus; Marthe Lindenbergh; Kevin Shannon; Michael T McManus; Jeroen P Roose
Journal:  Cell Rep       Date:  2019-04-09       Impact factor: 9.423

Review 2.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.

Authors:  Annette Nørregaard; Stine Skov Jensen; Jesper Kolenda; Charlotte Aaberg-Jessen; Karina Garnier Christensen; Poul Henning Jensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  Neurotox Res       Date:  2011-12-28       Impact factor: 3.911

4.  Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.

Authors:  E K Rowinsky; M J Citardi; D A Noe; R C Donehower
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity.

Authors:  C R Pinkerton; B McDermott; T Philip; P Biron; C Ardiet; H Vandenberg; M Brunat-Mentigny
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

7.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; L K Kvols; S E Vogl; D J Glover; R G Hahn; D L Trump; P P Carbone; J D Earle; T E Davis
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

10.  Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Authors:  Charles O Noble; Zexiong Guo; Mark E Hayes; James D Marks; John W Park; Christopher C Benz; Dmitri B Kirpotin; Daryl C Drummond
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-30       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.